GLAND.NS Cash Flow
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹3.64 Bn | ₹9.97 Bn | ₹9.15 Bn | ₹10.31 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹12.08 Bn | ₹-17.57 Bn | ₹17.05 Bn | ₹1.38 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹0.15 Bn | ₹-7.99 Bn | ₹-4.33 Bn | ₹-4.17 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.03 Bn | ₹0.08 Bn | ₹0.13 Bn | ₹0.51 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹15.90 Bn | ₹-15.52 Bn | ₹21.99 Bn | ₹8.03 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹3.19 Bn | ₹19.09 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).